ClinicalTrials.gov posted results on 2026-08-07 for NCT04729959, a phase 2 study of atezolizumab and tocilizumab with stereotactic radiation in recurrent glioblastoma. The record included 61 participants and reported safety-run and efficacy outcomes across non-surgical and surgical cohorts.

Background

The trial studied Diffuse Astrocytoma, IDH-Wildtype and Recurrent Glioblastoma. The posted brief summary says the study tested the best dose and effect of tocilizumab in combination with atezolizumab and stereotactic radiation therapy in patients whose tumor returned after initial treatment.

Trial design

The record describes an ACTIVE_NOT_RECRUITING phase 2 study with a 61-participant enrollment. Interventions included atezolizumab and tocilizumab. The posted results separate a non-surgical cohort safety run-in from phase 2 non-surgical outcomes and a surgical cohort comparing neoadjuvant combinations.

Key results

In the non-surgical safety run-in, the posted maximum-tolerated dose was 8 mg/kg. Dose-limiting toxicities were reported in 1 participant in Arm 1, 0 participants in Arm 2, and 0 participants in Arm 3.

For the phase 2 non-surgical cohort, the objective radiographic response rate was 1 participant. Median progression-free survival was 3.2 months, and median overall survival was 10.2 months.

In the surgical cohort, median progression-free survival was 3.5 months with neoadjuvant tocilizumab plus atezolizumab and 6.2 months with neoadjuvant atezolizumab alone. Median overall survival was 6.1 months for the combination arm, while the posted result for the atezolizumab-alone arm was NA.

What this means

The posted results provide an early readout on feasibility, toxicity, and disease control for an atezolizumab-based approach in recurrent glioblastoma. The dataset shows a tolerated non-surgical dose of 8 mg/kg and reports survival outcomes, but the single-arm and cohort-specific structure limits direct comparison across all arms.

Source

This information is based on ClinicalTrials.gov results posted for NCT04729959 on 2026-08-07. The record is available at clinicaltrials.gov.